cholangiocarcinoma
ASLAN Raises US$34 Million For Immuno-Oncology
The US$34 million in Series C funding will be used to complete at least ten clinical studies for ASLAN’s lead compound, ASLAN001.
ASLAN & Hyundai Pharm Collaborate To Develop Cancer Drug
The two companies will conduct clinical trials to assess varlitinib in the treatment of aggressive bile duct cancer, a disease prevalent in South Korea.
ASLAN’s Bile Duct Cancer Drug Given FDA Orphan Drug Status
ASLAN001 has been awarded orphan drug designation to treat cholangiocarcinoma, a rare and aggressive form of bile duct cancer.
Bile Duct Cancers Have Country-Specific Characteristics
Scientists have found that bile duct cancers from Singapore, Thailand, and Romania are very different when analyzed at the molecular level.
Novel Gene Mutations Implicated In Bile Duct Cancer Caused By Liver Fluke Infection
Investigators from Singapore and Thailand have discovered new bile duct cancer-associated gene mutations that are caused by a type of parasitic flatworm infection.
